Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Other financing activities (2018 - 2022)

Historic Other financing activities for Editas Medicine (EDIT) over the last 5 years, with Q2 2022 value amounting to $367000.0.

  • Editas Medicine's Other financing activities fell 3022.81% to $367000.0 in Q2 2022 from the same period last year, while for Jun 2022 it was $1.5 million, marking a year-over-year increase of 32.87%. This contributed to the annual value of $979000.0 for FY2022, which is 1501.74% down from last year.
  • Per Editas Medicine's latest filing, its Other financing activities stood at $367000.0 for Q2 2022, which was down 3022.81% from $526000.0 recorded in Q2 2021.
  • In the past 5 years, Editas Medicine's Other financing activities ranged from a high of $526000.0 in Q2 2021 and a low of $283000.0 during Q2 2019
  • For the 5-year period, Editas Medicine's Other financing activities averaged around $377600.0, with its median value being $362000.0 (2018).
  • Per our database at Business Quant, Editas Medicine's Other financing activities surged by 5028.57% in 2021 and then tumbled by 3022.81% in 2022.
  • Over the past 5 years, Editas Medicine's Other financing activities (Quarter) stood at $362000.0 in 2018, then fell by 21.82% to $283000.0 in 2019, then rose by 23.67% to $350000.0 in 2020, then skyrocketed by 50.29% to $526000.0 in 2021, then tumbled by 30.23% to $367000.0 in 2022.
  • Its last three reported values are $367000.0 in Q2 2022, $526000.0 for Q2 2021, and $350000.0 during Q2 2020.